Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Servier Expands Its Immuno-Oncology Presence With Sorrento PD-1 Deal

Executive Summary

Servier SA has moved to broaden its immune-oncology pipeline by signing a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento Therapeutics Inc.'s anti-PD-1 monoclonal antibody (mAb) STI-A1110, adding to its ongoing CAR-T efforts.

You may also be interested in...



Biopharma Quarterly Dealmaking Statistics, Q3 2016

In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.

Deal Watch: Flagship Ventures Doubles Down On Microbiome

Two of the VC's biotechs merged to create an immuno-microbiome company, while Seres is working with Emulate on better tech for microbiome research. UK specialty pharma Martindale acquired small hospital products-focused UK firm Viridian, and Bayer and X-Chem expanded their drug discovery alliance.

Servier and Cellectis sign $850m cancer collaboration

Servier has signed a strategic collaboration agreement with Cellectis to develop and commercialize up to six cancer products in a deal potentially worth $850m.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel